Why is aspirin considered a cornerstone therapy for cardiovascular prevention?

Aspirin is regarded as a cornerstone therapy for cardiovascular prevention primarily due to its long history of research and proven efficacy. The use of aspirin in reducing the risk of cardiovascular events, such as heart attacks and strokes, is well-supported by extensive clinical trials and studies that have established its benefits. Research has consistently shown that aspirin effectively inhibits platelet aggregation, which is a crucial factor in the formation of blood clots that can lead to cardiovascular incidents.

This evidence base, accumulated over decades, highlights aspirin's role in both primary and secondary prevention strategies. For individuals with existing cardiovascular disease or those at high risk, aspirin has been shown to significantly reduce morbidity and mortality rates associated with these conditions. The reliability of the data supporting aspirin's use makes it a trusted and foundational treatment choice in preventive cardiology.

While factors such as cost and availability are important for practical considerations, they do not encompass the critical aspect of efficacy that solidifies aspirin's position in therapy. Additionally, although aspirin is beneficial for many patients, it may not be universally suitable for all demographics due to potential contraindications or risks of bleeding; therefore, aspirin's role is best understood within the context of clinical evidence rather than broad demographic application.